Navigation Links
FDA approves CLARINEX-D 12 HOUR for seasonal allergic rhinitis

Food and Drug Association as approved the drug CLARINEX-D 12 HOUR for use in treating symptoms of seasonal allergic rhinitis. // CLARINEX-D 12 HOUR is a drug containing a combination of desloratadine 2.5 mg and pseudoephedrine sulfate, USP 120 mg. FDA has approved the drug for use in persons above 12 years of age. The drug has been found effective in curing persons with nasal and non-nasal symptoms occurring due to seasonal allergic rhinitis. Two clinical studies in 1,248 patients have found that the drug CLARINEX-D is found to be more effective in controlling allergic symptoms than the drug psueoephedrine alone.

The drug contains a delivery system, which delivers psudoephedrine in a consistent manner, and a dosage of two times a day of the nasal drug is found to be effective in controlling symptoms of allergic rhinitis and relieves nasal blockage and congestion, running nose, sneezing, watery eyes and itchy throat. The drug is found to be very effective in controlling allergic symptoms but has been found to be associated with mild side effects of insomnia, headache, pharyngitis, weakness and fatigue.


Page: 1

Related medicine news :

1. FDA approves new device to treat womens bleeding disorder
2. FDA approves surgical gel
3. FDA approves drug for rare liver disease
4. FDA approves first pocket-sized EKG machine
5. FDA approves Watson Pharmaceuticals Oxytrol patch
6. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
7. Madras High Court Disapproves of Comparative Advertisements
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. Study disapproves a new Asthma inhaler
10. GMC Disapproves Internet Doctor
11. Old flu drugs not effective against seasonal influenza
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology: